(Q42688865)

4 November 2017

The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements (English)

1 reference

4 November 2017

1 reference

2

Michael F Green

1 reference

4 November 2017

1

Philip D Harvey

1 reference

4 November 2017

Christopher Bowie

3

1 reference

PubMed ID

16783539

4 November 2017

Antony Loebel

series ordinal

4

1 reference

4 November 2017

17 June 2006

1 reference

4 November 2017

1 reference

4 November 2017

187

1 reference

4 November 2017

3

1 reference

4 November 2017

356-363

1 reference

https://scigraph.springernature.com/pub.10.1007/s00213-006-0432-1

4 November 2017

0 references

cites work

What are the functional consequences of neurocognitive deficits in schizophrenia?

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00213-006-0432-1

One hundred years of schizophrenia: a meta-analysis of the outcome literature.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00213-006-0432-1

Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.

21 January 2018

1 reference

12 December 2020

Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale

1 reference

12 December 2020

Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness.

1 reference

12 December 2020

Stability of cognitive performance in older patients with schizophrenia: an 8-week test-retest study.

1 reference

12 December 2020

The relationship of neuropsychological test performance with the PANSS in antipsychotic naïve, first-episode psychosis patients

1 reference

12 December 2020

Baseline neurocognitive deficits in the CATIE schizophrenia trial.

1 reference

12 December 2020

Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: a follow-up study.

1 reference

12 December 2020

Does cognitive function improve with quetiapine in comparison to haloperidol?

1 reference

12 December 2020

Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia

1 reference

12 December 2020

Cognitive remediation and vocational rehabilitation for schizophrenia

1 reference

12 December 2020

The functional significance of symptomatology and cognitive function in schizophrenia

1 reference

12 December 2020

Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness

1 reference

12 December 2020

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol

1 reference

12 December 2020

A regulatory perspective on psychiatric syndromes in Alzheimer disease.

1 reference

12 December 2020

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.

1 reference

12 December 2020

Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia

1 reference

12 December 2020

Cognitive training and supported employment for persons with severe mental illness: one-year results from a randomized controlled trial

1 reference

12 December 2020

Cognitive functioning, symptoms, and work in supported employment: a review and heuristic model

1 reference

12 December 2020

Schizophrenic performance when distractors are present: Attentional deficit or differential task difficulty?

1 reference

12 December 2020

California Verbal Learning Test practice effects in a schizophrenia sample

1 reference

12 December 2020

Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. A multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. The PANSS Study Group.

1 reference

12 December 2020

The continuous performance test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients.

1 reference

12 December 2020

Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS.

1 reference

12 December 2020

Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior

1 reference

12 December 2020

1 reference

12 December 2020

The convergence of neuropsychological testing and clinical ratings of cognitive impairment in patients with schizophrenia

1 reference

12 December 2020

Cognitive deficits as treatment targets in schizophrenia

1 reference

12 December 2020

Guanfacine treatment of cognitive impairment in schizophrenia

1 reference

12 December 2020

Cognitive functioning and positive and negative symptoms in schizophrenia

1 reference

12 December 2020

Medicine. What are the right targets for psychopharmacology?

1 reference

12 December 2020

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study

1 reference

12 December 2020

Approaches to cognitive remediation of neuropsychological deficits in schizophrenia: a review and meta-analysis

1 reference

12 December 2020

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

1 reference

12 December 2020

10.1007/S00213-006-0432-1

Identifiers

DOI

1 reference

PubMed ID

16783539

Dimensions Publication ID

4 November 2017

0 references

1 reference

PubMed ID

16783539